Medical device company, Oncosil
(ASX:OSL) has announced a third patient in its global study has undergone a surgical resection.
The business is conducting a global pancreatic cancer clinical study.
The first patients in the trial have been successfully implanted with Oncosil device.
The company says the device continues to be well tolerated with no safety concerns to date.
Shares in Oncosil
(ASX:OSL) are trading 4.17 per cent higher to 13 cents.
